Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients

British Journal of Clinical Pharmacology

Volumn 47, Issue 4, 1999, Pages 351-356

  Van Der Heyden, S A M ^a   Highley, M S ^b   De Bruijn, Ernst A ^a,d   Tjaden, U R ^a   Reeuwijk, H J E M ^e   Van Slooten, H ^c   Van Oosterom, A T ^a   Maes, R A A ^e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^c Deaconess Hospital   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e NONE

Author keywords

Administration oral; Bioavailability; Doxifluridine; Fluorouracil; Pharmacokinetics; Phase I clinical trials

Indexed keywords

ANTIMETABOLITE; DIHYDROFLUOROURACIL; FLOXURIDINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOXICITY; DRUG URINE LEVEL; HUMAN; INTESTINE CANCER; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; FLOXURIDINE; HUMANS; MIDDLE AGED; NEOPLASMS;

EID: 0032956481     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00899.x     Document Type: Article

References (29)

1. 1 Cohen JL, Irwin LJ, Marshall GJ, Darvey H, Bateman JR. Clinical pharmacology of oral and intravenous 5-fluorouracil (NSC 19893). Cancer Chemother Rep 1974; 58; 723-731.
2. 2 Christophidis N, Vajda FJE, Lucas I, Drummer O, Moon WJ, Lewis WJ. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokin 1978; 3: 330-336.
3. 3 Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokin 1989; 16: 215-237.
4. 4 Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colotectal carcinoma: a mid-atlantic oncology program study. J Clin Oncol 1989; 7: 425-432.
5. 5 Calabresi F, Repetto M. Doxifluridine in advanced colorectal cancer. J Surg Oncol Suppl 1991; 2: 124-128.
6. 6 Abele R, Alberto P, Kaplan S, et al. Phase II study of doxifluridine in advanced colorectal adenocarcinoma. J Clin Oncol 1983; 1: 750-754.
7. 7 De Bruijn EA, Van Oosterom AT, Tjaden UR, Reeuwijk HJEM, Pinedo HM. Pharmacology of 5′-deoxy-5 fluorouridine in patients with resistant ovarian cancer. Cancer Res 1985; 45: 5931-5935.
8. 8 Schaaf LJ, Dobbs BR, Edwards IR, Perrier DC. The in vitro stability of doxifluridine in whole blood plasma. Eur J Clin Pharmacol 1988; 34: 533-534.
9. 9 Murphy RF, Balis FM, Poplack DC. Stability of 5-fluorouracil in whole blood and plasma. Clin Chem 1987; 33: 2299-2300.
10. 10 De Bruijn EA, Remeyer L, Tjaden UR, et al. Non-linear pharmacokinetics of 5-fluorouracil as described by in vivo behaviour of 5,6 dihydro-5-fluorouracil. Biochem Pharmacol 1986 35: 2461-2465.
11. 11 Van den Bosch N, Driessen O, Van de Velde EA, Erkelens C. The stability of 5,6-dihydrofluorouracil in plasma and the consequences for its analysis. Ther Drug Monit 1987 9: 443-447.
12. 12 De Bruijn EA, Tjaden UR, Van Oosterom AT, Leeflang P, Leclereq PA. Determination of the underivatized antineoplastic drugs cyclophosphamide and 5-fluorouracil and some of their metabolites by capillary gas chromatography combined with electron-capture nitrogen phosphorus selective detection. J Chromatogr 1983; 279: 603-608.
13. 13 De Bruijn Leclereq PA, Van Oosterom AT, et al. Capillary gas chromatography in cancer research. Proc Eighth Int Symp Capillary Chromatoraphy; Dr Alfred Huethig, -Verlag, Heidelberg 1987 (Sandra P, ed.): 754-763.
14. 14 World Health Organization. Handbook for reporting results of cancer treatment. WHO Offset Publication Geneva, 1979: 48.
15. 15 Clarkson B, O'Connor A, Winston LR, Hutchison D. The physiologic disposition of 5 fluorouracil and 5-fluoro-2′-deoxyuridine in man. Clin Pharmacol Ther 1964; 5: 581-610.
16. 16 De Bruijn EA, Slee PH, ThJ, Van Oosterom AT, Lameijer DW, Roozendaal KJ, Tjaden UR. Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharm Weekbl Sci Ed 1988; 10: 200-206.
17. 17 Keizer HJ, De Bruijn EA, Tjaden UR, De Clereq E. Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E) -5-(2-bromovinyl) -2′-deoxyuridine. J Cancer Res Clin Oncol 1994; 120: 545-549.
18. 18 Kimura K, Saifo T, Taguchi T. Experimental and clinical sudies on the anticancer agent doxifluridine (5′-dFUR). J Int Med Res 1988; 16(Suppl 2): 1B-37B.
19. 19 Bajetta E, Colleoni M, Di Bartolomeo M, et al. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol 1995; 13: 2613-2619.
20. 20 Vermeulen PB, Verhoeven D, Hubens G, et al. Microvessel density; endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann Oncol 1995; 6: 59-64.
21. 21 Vermeulen PB, Verhoeven D, Fierens H, et al. Microvessel quantification in primary colorectal carcinoma: an immunochemical study. Br J Cancer 1995; 71: 340-343.
22. 22 Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet derived endothelial cell growth factor. Nature 1989; 338: 557-562.
23. 23 O'Brien T, Cranston D, Fuggle S, Bicknell R, Harns AL. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995; 55: 510-513.
24. 24 Van der Heyden S, Gheuens E, De Bruijn EA, Van Oosterom A, Maes R. P-Glycoprotein: Clinical significance and methods of analysis. Crit Rev Clin Lab Sci 1995; 32: 221-264.
25. 25 Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-141.
26. 26 Geng Y, Gheuens E, De Bruijn EA. Activation and cytotoxicity of 5′-deoxy-5-fluoronridine in c-H ras transformed NIH 3T3 cells. Biochem Pharmacol 1991; 41: 301-303.
27. 27 Peters GJ, Wets M, Keepers YPAM, et al. Transformation of mouse fibroblasts with the oncogenes H-ras or trh is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 1993; 54: 450-455.
28. 28 Van der Heyden SAM, Van de Putte M, Van Oosterom AT, De Bruijn EA, Van Elsas A, Schrier PI. N-ras and c-myc expression in human melanoma cell lines as molecular basis for 5′-deoxy-S-fluorouridine cytotoxicity. Biochem Pharmacol (in press).
29. 29 Van der Heyden S, Gheuens E, Van de Vrie W, et al. 5′-Deoxy-5 fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression. Jpn J Cancer Res 1994; 85: 13-16.